You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2025

Details for Patent: 7,214,684


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,214,684
Title:Methods for the treatment of allergic rhinitis
Abstract:Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Inventor(s): Aberg; A. K. Gunnar (Westborough, MA), McCullough; John R. (Worcester, MA), Smith; Emil R. (Shrewsbury, MA)
Assignee: Sepracor Inc. (Marlborough, MA)
Application Number:10/989,514
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 7,214,684

Introduction

United States Patent 7,214,684, hereafter referred to as the '684 patent, is a significant intellectual property asset related to the pharmaceutical industry, particularly concerning the drug desloratadine, which is marketed under the brand name Clarinex. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Background of the Patent

The '684 patent is owned by Sepracor Inc. and the University of Massachusetts (UMass), and it pertains to specific formulations and methods related to desloratadine, an antihistamine used to treat allergies. The patent was part of a series of patents that protected the exclusive rights to manufacture, use, and sell desloratadine products[2][5].

Scope of the Patent

The scope of the '684 patent encompasses specific claims related to the composition, formulation, and method of use of desloratadine. Here are some key aspects:

Composition and Formulation

  • The patent covers specific formulations of desloratadine, including orally disintegrating tablets containing 2.5 and 5 milligrams of the active ingredient. These formulations are designed to provide rapid dissolution and absorption, enhancing the drug's efficacy[2][5].

Method of Use

  • The patent also includes claims related to the method of using desloratadine for treating allergic conditions. This includes the administration route, dosage, and any specific instructions for use[2].

Claims of the Patent

The claims of the '684 patent are detailed and specific, ensuring broad protection for the inventors and assignees. Here are some key claim types:

Independent Claims

  • These claims define the broadest scope of the invention. For example, Claim 1 might describe the composition of the orally disintegrating tablet, including the active ingredient desloratadine and other excipients[2].

Dependent Claims

  • These claims further narrow down the invention by adding additional limitations. For instance, a dependent claim might specify the exact dosage form or the method of manufacturing the tablet[2].

Patent Landscape

Understanding the patent landscape is crucial for assessing the strength and potential challenges to the '684 patent.

Related Patents

  • The '684 patent is part of a family of patents related to desloratadine. Other patents in this family include U.S. Patent Nos. 7,211,582 and 7,214,683. These patents collectively provide comprehensive protection for various aspects of desloratadine formulations and uses[2][5].

International Protection

  • To ensure global protection, similar patents would have been filed in other jurisdictions. For example, using databases like the European Patent Office's esp@cenet or the World Intellectual Property Organization's PATENTSCOPE can reveal international counterparts of the '684 patent[1].

Litigation and Challenges

  • The '684 patent has been involved in several patent infringement cases. For instance, Sepracor and UMass have litigated against generic drug manufacturers like Orchid and Belcher, who sought to market generic versions of desloratadine before the patent's expiration[2][5].

Tools for Analyzing Patents

Several tools and resources are available for analyzing patents like the '684 patent:

USPTO Patent Public Search

  • This tool allows users to search for prior art and analyze the claims and scope of patents. It replaces legacy tools like PubEast and PubWest and provides enhanced access to prior art[1].

Global Dossier

  • This service provides access to the file histories of related applications from participating IP Offices, helping users to see the patent family and related applications[1].

Patent Claims Research Dataset

  • This dataset from the USPTO contains detailed information on claims from U.S. patents and applications, which can be used to analyze the scope and trends of patent claims[3].

Impact on the Pharmaceutical Industry

The '684 patent and its related patents have significant implications for the pharmaceutical industry:

Exclusivity and Market Protection

  • The patent ensures exclusivity for Sepracor and its licensees, preventing generic competition until the patent expires. This exclusivity is crucial for recouping investment in research and development[2][5].

Innovation and R&D

  • Patents like the '684 patent incentivize innovation by providing a period of exclusive rights, which encourages further research and development in the pharmaceutical sector.

Key Takeaways

  • Scope and Claims: The '684 patent covers specific formulations and methods related to desloratadine, including orally disintegrating tablets and their use in treating allergic conditions.
  • Patent Landscape: The patent is part of a family of patents and has been involved in several litigation cases to protect its exclusivity.
  • Tools for Analysis: Resources like the USPTO Patent Public Search, Global Dossier, and the Patent Claims Research Dataset are essential for analyzing the scope and claims of patents.
  • Industry Impact: The patent plays a critical role in protecting market exclusivity and encouraging innovation in the pharmaceutical industry.

FAQs

Q: What is the main subject of United States Patent 7,214,684? A: The main subject of the '684 patent is specific formulations and methods related to the antihistamine desloratadine, marketed under the brand name Clarinex.

Q: How can one search for prior art related to this patent? A: One can use the USPTO Patent Public Search tool or other international databases like esp@cenet or PATENTSCOPE to search for prior art.

Q: What are the implications of the '684 patent for generic drug manufacturers? A: The patent prevents generic drug manufacturers from marketing generic versions of desloratadine until the patent expires, thus protecting the exclusivity of the original patent holders.

Q: What tools are available for analyzing the claims and scope of patents like the '684 patent? A: Tools like the USPTO Patent Public Search, Global Dossier, and the Patent Claims Research Dataset are available for analyzing the claims and scope of patents.

Q: How does the '684 patent impact innovation in the pharmaceutical industry? A: The patent incentivizes innovation by providing a period of exclusive rights, which encourages further research and development in the pharmaceutical sector.

Sources

  1. USPTO - Search for patents. Retrieved from https://www.uspto.gov/patents/search
  2. Case 3:07-cv-04623-MLC-TJB Document 1 Filed 09/26/07. Retrieved from https://insight.rpxcorp.com/litigation_documents/2326184
  3. USPTO - Patent Claims Research Dataset. Retrieved from https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. USA.gov - U.S. Patent and Trademark Office (USPTO). Retrieved from https://www.usa.gov/agencies/u-s-patent-and-trademark-office
  5. Justia - SETTLEMENT AGREEMENT | GeoPharma, Inc.. Retrieved from https://contracts.justia.com/companies/geopharma-inc-43867/contract/726021/

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 7,214,684

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

International Family Members for US Patent 7,214,684

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Australia 4512696 ⤷  Subscribe
Australia 707541 ⤷  Subscribe
Austria 339956 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 3 of 3 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.